Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidative hfRT With Durvalumab After dCRT for Stage III NSCLC
NCT04748419Phase 2Terminated
- Sponsor
- University of Nebraska
- Start
- Jul 2021
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by University of Nebraska. Started Jul 2021; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04748419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04748419.